Argenica Therapeutics Limited is an Australia-based biotechnology company, developing...Argenica Therapeutics Limited is an Australia-based biotechnology company, developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischemic encephalopathy (HIE). The Company has completed a Phase I clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. It has completed dosing in a Phase II clinical trial in ischaemic stroke patients and continues to generate preclinical data in other neurological conditions, including in TBI and HIE.More
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
